Cero Therapeutics Holdings, Inc. SEC filings CEROW
Cero Therapeutics Holdings, Inc. has 445 filings in SEC EDGAR's recent list, going back to Jul 8, 2021. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 7, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25-NSE | Delisting notice | Jul 13, 2026 | — |
| NT 10-K | Notification of late filing | Apr 1, 2026 | Dec 31, 2025 |
| EFFECT | Filing | Dec 11, 2025 | — |
| CORRESP | Letter to the SEC | Dec 9, 2025 | — |
| NT 10-Q | Notification of late filing | Nov 17, 2025 | Sep 30, 2025 |
| EFFECT | Filing | Aug 15, 2025 | — |
| NT 10-Q | Notification of late filing | Aug 15, 2025 | Jun 30, 2025 |
| CORRESP | Letter to the SEC | Aug 14, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2025 | — |
| EFFECT | Filing | Jul 29, 2025 | — |
| CORRESP | Letter to the SEC | Jul 28, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 25, 2025 | — |
| EFFECT | Filing | May 29, 2025 | — |
| UPLOAD | Letter from the SEC | May 7, 2025 | — |
| D | Filing | May 6, 2025 | — |
| CORRESP | Letter to the SEC | May 2, 2025 | — |
| PRER14A | Proxy statement | May 2, 2025 | — |
| UPLOAD | Letter from the SEC | May 1, 2025 | — |
| NT 10-K | Filing | Apr 1, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Feb 5, 2025 | — |
| CORRESP | Letter to the SEC | Feb 5, 2025 | — |
| CORRESP | Letter to the SEC | Feb 3, 2025 | — |
| CORRESP | Letter to the SEC | Jan 31, 2025 | — |
| CORRESP | Letter to the SEC | Jan 28, 2025 | — |
| CORRESP | Letter to the SEC | Jan 27, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 26, 2024 | — |
| EFFECT | Filing | Dec 5, 2024 | — |
| EFFECT | Filing | Dec 5, 2024 | — |
| CORRESP | Letter to the SEC | Dec 4, 2024 | — |
| CORRESP | Letter to the SEC | Dec 4, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2024 | — |
| CORRESP | Letter to the SEC | Nov 25, 2024 | — |
| NT 10-Q | Notification of late filing | Nov 14, 2024 | Sep 30, 2024 |
| UPLOAD | Letter from the SEC | Nov 4, 2024 | — |
| DEFR14A | Proxy statement | Oct 18, 2024 | — |
| D | Filing | Oct 4, 2024 | — |
| PRER14A | Revised preliminary proxy statement | Aug 19, 2024 | — |
| EFFECT | Filing | Jul 5, 2024 | — |
| CORRESP | Letter to the SEC | Jul 3, 2024 | — |
| CORRESP | Letter to the SEC | Jun 27, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 13, 2024 | — |
| CORRESP | Letter to the SEC | Jun 5, 2024 | — |
| UPLOAD | Letter from the SEC | May 16, 2024 | — |
| NT 10-Q | Notification of late filing | May 16, 2024 | Mar 31, 2024 |
| EFFECT | Filing | May 1, 2024 | — |
| CORRESP | Letter to the SEC | Apr 29, 2024 | — |
| CORRESP | Letter to the SEC | Apr 26, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2024 | — |
| NT 10-K | Notification of late filing | Apr 2, 2024 | Dec 31, 2023 |
| D | Filing | Feb 23, 2024 | — |
| 25-NSE | Delisting notice | Feb 14, 2024 | — |
| 425 | 8-k | Feb 14, 2024 | — |
| 425 | Current report | Feb 12, 2024 | — |
| 425 | Current report | Feb 6, 2024 | — |
| EFFECT | Filing | Jan 19, 2024 | — |
| CORRESP | Letter to the SEC | Jan 18, 2024 | — |
| CORRESP | Letter to the SEC | Jan 8, 2024 | — |
| 425 | Current report | Jan 5, 2024 | — |
| CORRESP | Letter to the SEC | Dec 15, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2023 | — |
| CORRESP | Letter to the SEC | Dec 13, 2023 | — |
| 425 | Current report | Dec 11, 2023 | — |
| CORRESP | Letter to the SEC | Dec 11, 2023 | — |
| CORRESP | Letter to the SEC | Dec 6, 2023 | — |
| 425 | Current report | Sep 8, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 24, 2023 | — |
| 425 | Current report | Aug 14, 2023 | — |
| CORRESP | Letter to the SEC | Aug 11, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 2, 2023 | — |
| CORRESP | Letter to the SEC | Jul 19, 2023 | — |
| 425 | Amendment no. 1 to form 8-k | Jul 18, 2023 | — |
| 425 | Current report | Jul 10, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 5, 2023 | — |
| 425 | Current report | Jul 3, 2023 | — |
| 425 | Filing | Jun 5, 2023 | — |
| 425 | Filing | Dec 7, 2022 | — |
| 425 | Filing | Oct 31, 2022 | — |
| 425 | Filing | Oct 31, 2022 | — |
| EFFECT | Filing | Oct 5, 2021 | — |
| CERT | Filing | Oct 5, 2021 | — |
| 8-A12B | Filing | Oct 5, 2021 | — |
| CORRESP | Letter to the SEC | Oct 1, 2021 | — |
| CORRESP | Letter to the SEC | Oct 1, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 27, 2021 | — |
| DRS | Filing | Jul 8, 2021 | — |
Showing 86 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CERO (OTC), CEROW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1870404
- Former names
- CERO THERAPEUTICS HOLDINGS, INC. (until Oct 7, 2026); PHOENIX BIOTECH ACQUISITION CORP. (until Feb 14, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.